Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 3/20 | 0.33 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3925938 | 0.80 | SLC6A4 (0.38) | SLC6A4SLC6A2CYP2D6SLC6A3FPR2 | |
| SCHEMBL22736534 | 0.77 | SLC6A2 (0.36) | SLC6A4SLC6A2CHRNB2CHRNA4SLC6A3 | |
| SCHEMBL4598274 | 0.77 | SLC6A4 (0.47) | SLC6A4SLC6A2FPR2PROKR1IDO1 | |
| SCHEMBL1321806 | 0.74 | CYP26A1 (0.33) | CHRNB2CHRNA4 | |
| SCHEMBL3923712 | 0.74 | PDE4A (0.43) | SLC6A4FPR2PROKR1 | |
| SCHEMBL31508344 | 0.74 | DHODH (0.34) | CHRNB2CHRNA4IDO1 | |
| SCHEMBL29108191 | 0.73 | CYP11B1 (0.33) | CHRNB2CHRNA4 | |
| SCHEMBL14769877 | 0.71 | SLC6A4 (0.50) | SLC6A4SLC6A2CYP2D6SLC6A3 | |
| SCHEMBL17064623 | 0.71 | SLC6A3 (0.43) | SLC6A4SLC6A2CHRNB2CHRNA4SLC6A3 | |
| SCHEMBL16979030 | 0.71 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3FPR2PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384773-B2 | Thiazole compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| WO-2025096979-A1 | THIAZOLE COMPOUNDS AS KIT INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250145606-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384773-B2 | Thiazole compounds and methods of use thereof | TPMT, CYP11B2, ABAT | SLC6A4 979/4885SLC6A2 1272/4885CHRNB2 4487/4885 |
| US-20250145606-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | TPMT, CYP11B2, ABAT | SLC6A4 979/4885SLC6A2 1272/4885CHRNB2 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.